Navigation Links
Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
Date:6/4/2013

CHICAGO, June 4, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that multiple presentations from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were presented at the Annual Meeting of the American Society of Clinical Oncology.

Data presented included analyses of the 333 patients with relapsed or refractory acute myeloid leukemia (AML) from a Phase 2 clinical trial of quizartinib as monotherapy. In the study, quizartinib was administered orally, once-a-day, in 28-day treatment cycles until disease progression, elective hematopoietic stem cell transplantation (HSCT) or unacceptable toxicity. Based on the positive data from the Phase 2 clinical trial, as well as ongoing discussions with the Food and Drug Administration (FDA), Ambit is planning to initiate a Phase 3 clinical trial in FLT3-ITD positive patients with relapsed or refractory AML in early 2014.

Data Presentations

High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation with Quizartinib (AC220) in Patients with FLT3‑ITD Positive or Negative Relapsed/Refractory AML after Second Line Chemotherapy or Previous Bone Marrow Transplant (Abstract #7012)
Jorge Cortes , M.D., Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Data from 176 patients, aged 18 years or older, with either relapsed disease or who were refractory to second-line chemotherapy or HSCT were presented. Of the 136 FLT3 positive patients, 35 percent were successfully bridged to a potentially curative HSCT, with the greatest proportion receiving a HSCT after achieving a CRi (complete remission with incomplete hematologic recovery) with quizartinib. Additionally, 33 percent of patients who were bridged to HCST afte
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
2. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
3. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
4. Ambit Biosciences to Present at Two Upcoming Investor Conferences
5. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
6. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
7. Arteriocyte announces Launch of Compass Biomedical
8. TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
9. Elsevier Announces its Collaboration with Kasetsart University, Thailand
10. Celsion Corporation Announces $9.83 Million Registered Direct Offering
11. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... WALTHAM, Mass., Nov. 2, 2010 Repligen Corporation (Nasdaq: ... second quarter of fiscal year 2011, ended September 30, ... compared to total revenue of $5,421,000 for the second ... or 35%.  Bioprocessing product revenue for the second quarter ...
... Inc. (OTC Bulletin Board: WDST ), a ... therapies to restore the health of damaged tissues and ... newest advancements in regenerative medicine on November 9th, 2010 ... role in the commercialization of the therapeutic candidate, PermaDerm™, ...
... of a Nobel prize this year but research led ... Warwick has found molecular hooks on the surface of ... provide massive benefits to researchers using transmission electron microscopes. ... mechanisms. The research team, which includes Drs. Jeremy Sloan, ...
Cached Biology Technology:Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 2Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 3Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 4Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 5Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 6Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 7Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine 2Pivoting hooks of graphene's chemical cousin could revolutionize work of electron microscopes 2
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... in their blood are more likely to survive the disease, ... of vitamin D have half the risk of dying compared ... The study is the first to correlate total blood levels ... which includes that produced after exposure to sunlight and ... survival prospects. , The University of Edinburgh team tested ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
Breaking Biology News(10 mins):The impact of big data on health care: Health Affairs' July issue 2
... of great whales ever recorded? To answer that ... the Wildlife Conservation Society have joined experts from other ... Commission on the Patagonian coast of Argentina to try ... issue is the long-term conservation of the southern right ...
... "Four and 20 black birds baked in a pie" but ... analysis, means scientists now know there is one more species of ... thought. And if Dr. Gary Voelker has his way, he,ll soon ... deforestation now occurring across its native habitat. The bird ...
... resistance to sea lice treatments such as the pyrethroids ... Pyrethroid use still increased from 2008 to 2009, although ... are being used again due to resistance problems, e.g. ... been used since 1997, was also used again in ...
Cached Biology News:Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3African bird discovery proves there is something new under the sun 2
Request Info...
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
Request Info...
... E. coli containing a clone of the human ... Topoisomerase II alters the topological state of nucleic ... a transient break which generates a separate DNA ... double-stranded DNA passage mechanism, the enzyme can relax ...
Biology Products: